{"id":"tasonermin","rwe":[{"pmid":"41575505","year":"2026","title":"[Hyperthermic isolated limb perfusion with TNF-alpha and melphalan for the treatment of locally advanced soft-tissue sarcoma].","finding":"","journal":"Operative Orthopadie und Traumatologie","studyType":"Clinical Study"},{"pmid":"31216854","year":"2019","title":"Neoadjuvant Hypertermic Isolated Limb Perfusion in Treatment of Undifferentiated Spindle Cell Sarcoma of Lower Limb with Achieved Complete Pathologic Response.","finding":"","journal":"Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti","studyType":"Clinical Study"},{"pmid":"27739318","year":"2016","title":"[Hyperthermic Isolated Limb Perfusion Combined with Tasonermin - a Perfusion Leakage Monitoring Technique].","finding":"","journal":"Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti","studyType":"Clinical Study"},{"pmid":"18251718","year":"2008","title":"Drugs and their molecular targets: an updated overview.","finding":"","journal":"Fundamental & clinical pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"Biologic","category":"modality"},{"label":"L03AX11","category":"atc"},{"label":"Active","category":"status"},{"label":"Sarcoma of soft tissue","category":"indication"},{"label":"Boehringer Ingelheim International GmbH","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Boehringer Ingelheim International GmbH","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TASONERMIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:14:42.970724+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:14:50.403515+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:14:42.990081+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TASONERMIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:14:51.146363+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2107891/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:14:51.609618+00:00"}},"allNames":"beromun","offLabel":[],"synonyms":["tasonermin","beromun"],"timeline":[{"date":"1999-04-13","type":"positive","source":"DrugCentral","milestone":"EMA approval (Boehringer Ingelheim International GmbH)"}],"brandName":"Beromun","ecosystem":[{"indication":"Sarcoma of soft tissue","otherDrugs":[{"name":"olaratumab","slug":"olaratumab","company":"Eli Lilly And Co"},{"name":"pazopanib","slug":"pazopanib","company":"Novartis Pharms Corp"}],"globalPrevalence":null}],"mechanism":{"modality":"Biologic","explanation":"","oneSentence":"","technicalDetail":"Beromun's exact mechanism of action is unknown, but it is believed to involve the inhibition of a specific molecular target involved in cell proliferation and survival."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5212","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TASONERMIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TASONERMIN","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T02:43:16.640462","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:14:54.005829+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"pegademase","drugSlug":"pegademase","fdaApproval":"1990-03-21","relationship":"same-class"},{"drugName":"glatiramer acetate","drugSlug":"glatiramer-acetate","fdaApproval":"1996-12-20","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"histamine","drugSlug":"histamine","fdaApproval":"1939-04-25","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"plerixafor","drugSlug":"plerixafor","fdaApproval":"2008-12-15","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"elapegademase","drugSlug":"elapegademase","fdaApproval":"2018-10-05","relationship":"same-class"}],"genericName":"tasonermin","indications":{"approved":[{"name":"Sarcoma of soft tissue","source":"DrugCentral","snomedId":424952003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"pegademase","brandName":"pegademase","genericName":"pegademase","approvalYear":"1990","relationship":"same-class"},{"drugId":"glatiramer-acetate","brandName":"glatiramer acetate","genericName":"glatiramer acetate","approvalYear":"1996","relationship":"same-class"},{"drugId":"histamine","brandName":"histamine","genericName":"histamine","approvalYear":"1939","relationship":"same-class"},{"drugId":"plerixafor","brandName":"plerixafor","genericName":"plerixafor","approvalYear":"2008","relationship":"same-class"},{"drugId":"elapegademase","brandName":"elapegademase","genericName":"elapegademase","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03685890","phase":"PHASE1,PHASE2","title":"Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2019-04-01","conditions":["Melanoma","In-Transit Metastasis"],"enrollment":74,"completionDate":"2029-12-31"},{"nctId":"NCT01490047","phase":"PHASE1","title":"Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas","status":"WITHDRAWN","sponsor":"Ludwig Institute for Cancer Research","startDate":"2013-01","conditions":["Solid Tumors","Lymphomas"],"enrollment":0,"completionDate":""},{"nctId":"NCT01452958","phase":"NA","title":"Endotoxin & Cytokines. Do Protein Loss and Metabolic Effects Depend on Central Nervous System (CNS) Activation of Stress Hormones or on Local Mechanisms in Muscle and Fat?","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2010-06","conditions":["Inflammation","Glucose Metabolism Disorders"],"enrollment":24,"completionDate":"2013-01"}],"_emaApprovals":[{"date":"1999-04-13","status":"Authorised","company":"Boehringer Ingelheim International GmbH"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"008935","UNII":"23CA79S88F","INN_ID":"7581","RXNORM":"283746","UMLSCUI":"C0937851","chemblId":"CHEMBL2107891","ChEMBL_ID":"CHEMBL2107891","KEGG_DRUG":"D08562","DRUGBANK_ID":"DB11626","SNOMEDCT_US":"421147008"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Boehringer Ingelheim International GmbH","relationship":"Current Owner"}],"publicationCount":4,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L03AX11","allCodes":["L03AX11"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb","pmid":"41575505","title":"[Hyperthermic isolated limb perfusion with TNF-alpha and melphalan for the treatment of locally advanced soft-tissue sarcoma].","journal":"Operative Orthopadie und Traumatologie"},{"date":"2019 Spring","pmid":"31216854","title":"Neoadjuvant Hypertermic Isolated Limb Perfusion in Treatment of Undifferentiated Spindle Cell Sarcoma of Lower Limb with Achieved Complete Pathologic Response.","journal":"Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti"},{"date":"2016 Fall","pmid":"27739318","title":"[Hyperthermic Isolated Limb Perfusion Combined with Tasonermin - a Perfusion Leakage Monitoring Technique].","journal":"Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti"},{"date":"2008 Feb","pmid":"18251718","title":"Drugs and their molecular targets: an updated overview.","journal":"Fundamental & clinical pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Boehringer Ingelheim International GmbH","companyId":"boehringer-ingelheim","modality":"Recombinant protein","firstApprovalDate":"1999","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:14:54.005829+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}